Clinical Trials Browser

Phase 1/2 × INDUSTRY × ralimetinib × Clear all

NCT01663857 2019-09-11

A Study LY2228820 for Recurrent Ovarian Cancer

Phase 1/2 Completed

118 enrolled 18 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms